Back to Search Start Over

Comparative effectiveness of robot‐assisted radical cystectomy with intracorporeal urinary diversion vs open radical cystectomy for bladder cancer.

Authors :
Gabriel, Pierre‐Etienne
Pinar, Ugo
Lenfant, Louis
Parra, Jérôme
Vaessen, Christophe
Mozer, Pierre
Chartier‐Kastler, Emmanuel
Rouprêt, Morgan
Seisen, Thomas
Source :
BJU International. Oct2024, p1. 8p. 1 Illustration.
Publication Year :
2024

Abstract

Objectives Patients and Methods Results Conclusion To assess the comparative effectiveness of robot‐assisted radical cystectomy (RARC) with intracorporeal urinary diversion (ICUD) vs open radical cystectomy (ORC) for bladder cancer (BC).We conducted a real‐life monocentric study including all consecutive patients who underwent RARC with ICUD or ORC for BC at our institution from 2014 to 2023. Uni‐ and multivariable logistic and Cox regression analyses were used to compare perioperative, oncological and stricture outcomes between both groups by calculating odds (ORs) and hazard (HRs) ratios with their corresponding 95% confidence intervals (CIs), respectively.Overall, 316 patients underwent either RARC with ICUD (n = 228 [72.2%]) or ORC (n = 88 [27.8%]). The perioperative benefits of RARC vs ORC included decreased risks of major blood loss (OR 0.10, 95% CI 0.04–0.23; P < 0.001), perioperative transfusion (OR 0.30, 95% CI 0.16–0.57; P < 0.001), 90‐day major complications (OR 0.56, 95% CI 0.29–0.99; P = 0.04), and prolonged initial length of hospital stay (OR 0.20, 95% CI 0.09–0.35; P < 0.001), as well as more days alive and out of the hospital within 90 days of surgery (OR 2.56, 95% CI 1.46–4.6; P < 0.01). In addition, the use of RARC vs ORC was associated with a higher lymph node (LN) count (OR 3.35, 95% CI 1.83–6.30; P < 0.001), while there was no significant difference in recurrence‐free (HR 0.72, 95% CI 0.49–1.07; P = 0.1), cancer‐specific (HR 0.69, 95% CI 0.43–1.10; P = 0.1), overall (HR 0.76, 95% CI 0.47–1.20; P = 0.3) and uretero‐ileal stricture‐free (HR 1.18, 95% CI 0.62–2.25; P = 0.6) survival between both groups after a median (interquartile range) follow‐up of 42.3 (16.4–73.8) months.Our real‐world study supports the effectiveness of RARC with ICUD vs ORC for BC. We generally observed better perioperative outcomes, as well as similar oncological—except for higher LN count—and uretero‐ileal stricture outcomes after RARC with ICUD vs ORC. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
14644096
Database :
Academic Search Index
Journal :
BJU International
Publication Type :
Academic Journal
Accession number :
180385517
Full Text :
https://doi.org/10.1111/bju.16565